YOLT-204 / YolTech Therap - LARVOL DELTA

YOLT-204 in Patients With Hemoglobinopathies (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Guangzhou Women and Children's Medical Center

New P1 trial • Beta-Thalassemia • Genetic Disorders • Hematological Disorders • Sickle Cell Disease

YolTech Therapeutics to Initiate a Clinical Trial for YOLT-204, a First-in-Class Bone Marrow-Targeted In Vivo Gene Editing Therapy for β-Thalassemia (PRNewswire) - "YolTech Therapeutics...announced the initiation of a clinical trial for YOLT-204, an investigational therapy for the treatment of transfusion-dependent beta-thalassemia (TDT)....The clinical trial for YOLT-204 is a dose-escalation study to preliminarily examine the safety and efficacy of a single-dose regimen with YOLT-204 in TDT. If successful, YOLT-204 may eventually provide an off-the-shelf curative treatment for TDT patients without conditioning chemotherapy and HSCT (Hematopoietic Stem Cell Transplantation)."

Trial status • Beta-Thalassemia

A Pilot Study on the Safety and Efficacy of YOLT-204 for Transfusion-Dependent Beta-Thalassemia (clinicaltrials.gov) - P1 | N=3 | Not yet recruiting | Sponsor: First Affiliated Hospital of Guangxi Medical University

New P1 trial • Beta-Thalassemia • Genetic Disorders